Tardive Dyskinesia Therapeutics Market Size, Share, Growth and Global Industry Analysis By Type & Application, Regional Insights and Forecast to 2024-2032
Growth Factors Of Tardive Dyskinesia Therapeutics Market
The tardive dyskinesia therapeutics market size was valued at USD 2.33 billion in 2022, and the market is now projected to grow from USD 2.77 billion in 2023 to USD 5.09 billion by 2030, exhibiting a CAGR of 9.1% during the forecast period of 2024-2032.
During COVID-19, non-COVID healthcare offerings, inclusive of those for uncommon situations such as tardive dyskinesia, confronted declines because of safety restrictions. Diagnoses and treatments have been hindered, with restrained get right of entry to diagnostics and drug healing procedures. Pharmaceutical organizations saw decreased prescription numbers as non-emergency corporations closed, slowing down treatment approvals.
One crucial driver undoubtedly impacting the worldwide market is the growing global incidence of tardive dyskinesia. This motion ailment can arise as a aspect impact of lengthy-time period use of sure psychiatric medicines such as antipsychotics. As antipsychotic tablets are increasingly used in the treatment of conditions including schizophrenia, schizoaffective ailment, and bipolar disease, the prevalence of tardive dyskinesia is rising as a consequence.
A triumphing trend within the global market is the upward push in projects by way of market players to boom consciousness approximately the treatment of tardive dyskinesia via diverse campaigns. Currently, the only accepted tablets for this condition are deutetrabenazine (AUSTEDO) by means of Teva Pharmaceutical Industries Ltd. And valbenazine (INGREZZA) with the aid of Neurocrine Biosciences, Inc. These groups are expanding their purchaser base via launching revolutionary campaigns to educate about the signs and engage sufferers in their treatment manner.
Comprehensive Analysis Of Tardive Dyskinesia Therapeutics Market
The tardive dyskinesia therapeutics market growth is rising at an exponential rate due to its market segmentation. This marketplace enlargement successfully affords an in-depth local exam thinking about the dominant deliver and demand forces that effect the enterprise. These segmentations are methodically segregated by drug analysis and by distribution channel analysis. By drug analysis include, deutetrabenazine, valbenazine, and others. By distribution channel analysis include, drug stores, online pharmacies, hospital pharmacies, and drug stores & retail pharmacies.
The North America region lead the tardive dyskinesia therapeutics market share by benefitting a market size of USD 2.24 billion in 2022 due to full-size recognition inside the populace regarding the disorder and growing help from many public and private institutions the use of studies endowments to fasten the look at for this disease.
The pinnacle players inside the market play a critical function in the enterprise assuring market growth and placing marketplace requirements. These players include, SOM Biotech (Spain), Luye Pharma Group (China), Mitsubishi Tanabe Pharma Corporation (Japan), Teva Pharmaceutical Industries Ltd. (Israel), Neurocrine Biosciences, Inc. (U.S.). These market players provide a level-playing competitive landscape.
In March 2022, The Ministry of Health, Labor and Welfare has granted regulatory approval to Mitsubishi Tanabe Pharma Corporation for the use of DYSVAL tablets 40mg, a vesicular monoamine transporter kind 2 (VMAT2) inhibitor, as tardive dyskinesia therapeutics.
Segmentation Table
ATTRIBUTE DETAILS
Study Period 2019-2030
Base Year 2022
Estimated Year 2023
Forecast Period 2023-2030
Historical Period 2019-2021
Growth Rate CAGR of 9.1% from 2023 to 2030
Unit Value (USD billion)
Segmentation By Drug, Distribution Channel, and Region
By Drug Deutetrabenazine
Valbenazine
Others
By Distribution Channel Hospital Pharmacies
Drug Stores & Retail Pharmacies
Online Pharmacies
By Region U.S. (By Drug, By Distribution Channel)
Europe (By Drug, By Distribution Channel, By Country/Sub-Region)
- Germany
- U.K.
- France
- Italy
- Spain
- Rest of Europe
Asia Pacific (By Drug, By Distribution Channel, By Country/Sub-Region)
- China
- Japan
- India
- Australia
- Rest of Asia Pacific
Rest of the World (By Drug, By Distribution Channel)
Please Note: It will take 5-6 business days to complete the report upon order confirmation.
- 1. Introduction
- 1.1. Research Scope
- 1.2. Market Segmentation
- 1.3. Research Methodology
- 1.4. Definitions and Assumptions
- 2. Executive Summary
- 3. Market Dynamics
- 3.1. Market Drivers
- 3.2. Market Restraints
- 3.3. Market Opportunities
- 3.4. Market Trends
- 4. Key Insights
- 4.1. Prevalence of Tardive Dyskinesia, By Key Countries, 2022
- 4.2. Key Industry Developments
- 4.3. Pipeline Analysis
- 4.4. Economic Cost Burden for the Treatment of Tardive Dyskinesia
- 4.5. Regulatory & Reimbursement Scenario, By Key Regions
- 4.6. Impact of COVID-19 on the Market
- 5. Global Tardive Dyskinesia Therapeutics Market Analysis, Insights and Forecast, 2019-2030
- 5.1. Market Analysis, Insights and Forecast – By Drug
- 5.1.1. Deutetrabenazine
- 5.1.2. Valbenazine
- 5.1.3. Others
- 5.2. Market Analysis, Insights and Forecast – By Distribution Channel
- 5.2.1. Hospital Pharmacies
- 5.2.2. Drug Stores & Retail Pharmacies
- 5.2.3. Online Pharmacies
- 5.3. Market Analysis, Insights and Forecast – By Country/Region
- 5.3.1. U.S.
- 5.3.2. Europe
- 5.3.3. Asia Pacific
- 5.3.4. Rest of the World
- 6. U.S. Tardive Dyskinesia Therapeutics Market Analysis, Insights and Forecast, 2019-2030
- 6.1. Market Analysis, Insights and Forecast – By Drug
- 6.1.1. Deutetrabenazine
- 6.1.2. Valbenazine
- 6.1.3. Others
- 6.2. Market Analysis, Insights and Forecast – By Distribution Channel
- 6.2.1. Hospital Pharmacies
- 6.2.2. Drug Stores & Retail Pharmacies
- 6.2.3. Online Pharmacies
- 7. Europe Tardive Dyskinesia Therapeutics Market Analysis, Insights and Forecast, 2019-2030
- 7.1. Market Analysis, Insights and Forecast – By Drug
- 7.1.1. Deutetrabenazine
- 7.1.2. Valbenazine
- 7.1.3. Others
- 7.2. Market Analysis, Insights and Forecast – By Distribution Channel
- 7.2.1. Hospital Pharmacies
- 7.2.2. Drug Stores & Retail Pharmacies
- 7.2.3. Online Pharmacies
- 7.3. Market Analysis, Insights and Forecast – By Country/Sub-Region
- 7.3.1. Germany
- 7.3.2. U.K.
- 7.3.3. France
- 7.3.4. Italy
- 7.3.5. Spain
- 7.3.6. Rest of Europe
- 8. Asia Pacific Tardive Dyskinesia Therapeutics Market Analysis, Insights and Forecast, 2019-2030
- 8.1. Market Analysis, Insights and Forecast – By Drug
- 8.1.1. Deutetrabenazine
- 8.1.2. Valbenazine
- 8.1.3. Others
- 8.2. Market Analysis, Insights and Forecast – By Distribution Channel
- 8.2.1. Hospital Pharmacies
- 8.2.2. Drug Stores & Retail Pharmacies
- 8.2.3. Online Pharmacies
- 8.3. Market Analysis, Insights and Forecast – By Country/Sub-Region
- 8.3.1. China
- 8.3.2. Japan
- 8.3.3. India
- 8.3.4. Australia
- 8.3.5. Rest of Asia Pacific
- 9. Rest of the World Tardive Dyskinesia Therapeutics Market Analysis, Insights and Forecast, 2019-2030
- 9.1. Market Analysis, Insights and Forecast – By Drug
- 9.1.1. Deutetrabenazine
- 9.1.2. Valbenazine
- 9.1.3. Others
- 9.2. Market Analysis, Insights and Forecast – By Distribution Channel
- 9.2.1. Hospital Pharmacies
- 9.2.2. Drug Stores & Retail Pharmacies
- 9.2.3. Online Pharmacies
- 10. Competitive Analysis
- 10.1. Global Market Share Analysis (2022)
- 10.2. Company Profiles (Overview, Products, SWOT Analysis, Recent Developments, Strategies, Financials (Based on Availability))
- 10.2.1. Teva Pharmaceutical Industries Ltd.
- 10.2.1.1. Overview,
- 10.2.1.2. Products,
- 10.2.1.3. SWOT Analysis,
- 10.2.1.4. Recent Developments,
- 10.2.1.5. Strategies,
- 10.2.1.6. Financials (Based on Availability)
- 10.2.2. Neurocrine Biosciences, Inc.
- 10.2.2.1. Overview,
- 10.2.2.2. Products,
- 10.2.2.3. SWOT Analysis,
- 10.2.2.4. Recent Developments,
- 10.2.2.5. Strategies,
- 10.2.2.6. Financials (Based on Availability)
- 10.2.3. Mitsubishi Chemical Group Corporation.
- 10.2.3.1. Overview,
- 10.2.3.2. Products,
- 10.2.3.3. SWOT Analysis,
- 10.2.3.4. Recent Developments,
- 10.2.3.5. Strategies,
- 10.2.3.6. Financials (Based on Availability)
- 10.2.4. SOM BIOTECH
- 10.2.4.1. Overview,
- 10.2.4.2. Products,
- 10.2.4.3. SWOT Analysis,
- 10.2.4.4. Recent Developments,
- 10.2.4.5. Strategies,
- 10.2.4.6. Financials (Based on Availability)
- 10.2.5. Luye Pharma Group
- 10.2.5.1. Overview,
- 10.2.5.2. Products,
- 10.2.5.3. SWOT Analysis,
- 10.2.5.4. Recent Developments,
- 10.2.5.5. Strategies,
- 10.2.5.6. Financials (Based on Availability)
Research Assistance
Download our eBook: How to Succeed Using Market Research
Learn how to effectively navigate the market research process to help guide your organization on the journey to success.
Download eBook